{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/26597402"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Rituximab is very expensive, at least $10,000 per course of treatment.Emerging therapiesTherapies that specifically target plasma cells might be attractive for treating IgG4-related disease, but their safety would need to be carefully considered, and it is important to note that standards for acceptable toxicity, with regard to infection or other side effects, are understandably more stringent in" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "pubmedcentralcanada.ca" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/135648071"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/26597402"] } } }
